Multigenetic pharmacogenomics-guided treatment shows greater improvements on motor symptoms compared to usual therapy in Parkinson's disease: a small real-word prospective cohort study.

ABSTRACT:

Background

Dopamine replacement therapy is a cornerstone of Parkinson's disease treatment. In clinical practice, there is considerable variability in patients' responses, tolerability, and safety regarding anti-parkinsonian medications, which is largely influenced by genetic polymorphisms in pharmacokinetic and pharmacodynamic genes. However, the application of multigenetic pharmacogenomics-guided treatment (MPGT) to optimize therapeutic outcomes in Parkinson's disease (PD) remains under-explored. In this study, we conducted a prospective cohort investigation to evaluate the potential benefits of MPGT on motor symptoms in PD patients.

Methods

A total of 28 patients with PD were followed for 4 weeks. Among them, 22 patients underwent multigenetic pharmacogenomic testing, with

SUBMITTER: Li Y 

PROVIDER: S-EPMC11975922 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature